UK Drug Update - May 2003

Published: 1-May-2003
Regulatory


Bayer has brought out Avelox tablets containing 400mg of the fluoroquinolone moxifloxacin.

Gilead Sciences has made available Hepsera tablets containing 10mg of the antiviral adefovir dipivoxil.

Alcon Laboratories has launched Opatanol eye drops. The drops contain 1mg/ml of the selective antiallergic/antihistaminergic drug olopatadine (as hydrochloride).

IVAX Pharmaceuticals has added 50mg, 150mg and 200mg capsules of the antifungal agent fluconazole to its range of products.

AstraZeneca has marketed Symbicort 400/12 Turbohaler. The product contains 400µg of the corticosteroid budesonide and 12µg of the b-2 adrenoceptor stimulant formoterol. The company has also introduced Crestor tablets containing 10mg, 20mg and 40mg tablets of the HMG-CoA reductase inhibitor rosuvastatin (as calcium).

Lagap Pharmaceuticals has added the following products to its range of generic medicines: 150mg capsules of the antibiotic clindamycin; and 50mg, 150mg and 200mg capsules of the antifungal agent fluconazole.

Bayer has launched Levitra tablets containing 5mg, 10mg or 20mg tablets of the phosphodiesterase type 5 inhibitor vardenafil.

GlaxoSmithKline UK has brought out Avodart capsules. The capsules contain 0.5mg of the 5a-reductase inhibitor dutasteride.

Niche Generics has made available 50mg, 150mg and 200mg capsules of the antifungal agent fluconazole.

Alpharma has introduced 20mg tablets of the 5HT reuptake inhibitor paroxetine.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now